Moderna, Inc. Derivative Asset, Current
Moderna, Inc. (MRNA) had Derivative Asset, Current of $77.00 million as of 2022-09-30, per its 10-Q filed 2022-11-03.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DerivativeAssetsCurrent · last filed 2022-11-03
- 2022-09-30: Derivative Asset, Current $77.00M.
- 2022-06-30: Derivative Asset, Current $58.00M.
- 2022-03-31: Derivative Asset, Current $35.00M.
- 2021-12-31: Derivative Asset, Current $21.00M.
| Period end | Derivative Asset, Current |
|---|---|
| 2022-09-30 | $77.00M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $58.00M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $35.00M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $21.00M 10-Q · filed 2022-11-03 |
| 2021-09-30 | $51.00M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $30.00M 10-Q · filed 2021-08-05 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |